Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00050778
Status:
COMPLETED
Last Update Posted:
2015-01-08
First Post:
2002-12-19
Brief Title:
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif in Patients With Early Active Relapsing-Remitting Multiple Sclerosis
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Key Dates - Follows AllAPIJSON File Order
Start Date:
2002-12
Start Date Type:
None
Primary Completion Date:
2007-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-01
Completion Date Type:
ACTUAL
First Submit Date:
2002-12-19
First Submit QC Date:
December 20 2002
Study First Post Date:
2002-12-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2009-08-25
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-01-06
Last Update Post Date:
2015-01-08
Last Update Post Date Type:
ESTIMATED